A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy

Inclusion Criteria:

- Biopsy confirmation of Breast Cancer

- Breast Cancer has continued to grow after having received treatment with an aromatase
inhibitor

- Postmenopausal women defined as a women who has stopped having menstrual periods

- Evidence of hormone sensitivity

- Written informed consent to participate in the trial

Exclusion Criteria:

- Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane)

- Any hormonal therapy used to modify the course of an additional medical condition
after prior treatment with a non-steroidal aromatase inhibitor

- Treatment with an investigational or non-approved drug within one month

- An existing serious disease, illness, or condition that will prevent participation or
compliance with study procedures

- A history of allergies to any active or inactive ingredients of Faslodex or
Exemestane (i.e. castor oil or Mannitol)